News
BTCY
1.350
-8.78%
-0.130
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. The company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome. Soligenix, Inc. Shares surged 71.5% after the company was granted orphan drug designation for MarVax.
Benzinga · 4d ago
Weekly Report: what happened at BTCY last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at BTCY last week (0401-0405)?
Weekly Report · 04/08 11:27
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
NASDAQ · 04/04 13:55
Weekly Report: what happened at BTCY last week (0325-0329)?
Weekly Report · 04/01 11:25
Weekly Report: what happened at BTCY last week (0318-0322)?
Weekly Report · 03/25 11:28
12 Health Care Stocks Moving In Monday's Intraday Session
Fresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. Akso Health Group stock moved upwards by 29.0%. ChromaDex stock rose upwards by 27.91%. Trxade Health shares declined by 33.0% during the session.
Benzinga · 03/18 17:31
Weekly Report: what happened at BTCY last week (0311-0315)?
Weekly Report · 03/18 11:26
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
NASDAQ · 03/14 12:50
Biotricity Unveils That Improved Margins Resulted From Latest Advancements To Its Proprietary Cardiac AI Cloud Platform And Announces Plans For Continued Expansion Of Its Cardiac AI Cloud
Biotricity's AI automation engine has already proven to increase operational efficiency and support growth. The Healthcare AI Market is projected to soar to $208.2 billion and remote patient monitoring market anticipated to reach $96.67 billion by 2030. The company is now expanding its Cardiac AI platform, building anonymized clinical models to support clinical decisions. The cardiac AI clinical model is expected to file for FDA clearance by the end of the year.
Benzinga · 03/12 13:04
Weekly Report: what happened at BTCY last week (0304-0308)?
Weekly Report · 03/11 11:22
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
NASDAQ · 03/07 17:00
Biotricity (BTCY) Receives a Hold from H.C. Wainwright
TipRanks · 03/05 11:27
Weekly Report: what happened at BTCY last week (0226-0301)?
Weekly Report · 03/04 11:25
Weekly Report: what happened at BTCY last week (0219-0223)?
Weekly Report · 02/26 11:40
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
NASDAQ · 02/20 23:20
Biotricity Q3 2024 Adj EPS $(0.12) Beats $(0.44) Estimate, Sales $2.97M Miss $3.00M Estimate
Benzinga · 02/20 23:14
Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Fluor Corporation fell 7.7% to $38.84 on Tuesday following fourth-quarter results. The company's sales came in at $3.82 billion compared to expectations of $4.11 billion. TRxade Health, Inc. Shares jumped 214% in today's mid-day session.
Benzinga · 02/20 18:21
Earnings Scheduled For February 20, 2024
Barclays is likely to report quarterly earnings at $0.36 per share on revenue of $7.38 billion. Fresenius Medical Care is projected to report earnings for its fourth quarter. Other companies expected to report before the bell include Avanos and Expeditors.
Benzinga · 02/20 11:52
Biotricity Inc <BTCY.OQ> expected to post a loss of 44 cents a share - Earnings Preview
Biotricity Inc expected to report a 22.0% increase in quarterly revenue to $3 million from $2.46 million. The company is expected to post a loss of 44 cents a share for the period ending December 31 2023. BiotricITY expected to release results on February 21.
Reuters · 02/19 22:40
More
Webull provides a variety of real-time BTCY stock news. You can receive the latest news about Biotricity Inc through multiple platforms. This information may help you make smarter investment decisions.
About BTCY
Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patient’s electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.